PPARγ signalling pathway: molecular mechanisms and therapeutic potential in ligamentum flavum hypertrophy and lumbar spinal stenosis Authors: Xue Chen, Chen Zhu, Shuhan Yang, Yuan Zeng, Bo Zhang, Chen Liang, Ye Tian, Tuanjiang Liu, Shanxi Wang Published: 2026 ABSTRACT AbstractBackgroundLigamentum flavum hypertrophy (LFH) is a multifactor-mediated degenerative change in the spine. Due to its complex aetiology and pathology, there is no targeted therapy for LFH in the clinic. Therefore, it is urgent to explore its potential mechanism and develop new therapeutic methods, which are conducive to the early recovery of patients. Peroxisome proliferator activated receptor γ (PPARγ), a nuclear receptor regulated by synthetic ligands and endogenous cellular lipids, is involved in a variety of biological processes. Currently, increasing evidence suggests that PPARγ may serve as a new pathway to guide the targeted treatment of LFH. Consequently, therapeutically harnessing the PPARγ signalling pathway to inhibit LFH could become a central focus of current research and clinical translation.Main bodyLFH involves multiple pathological processes, including inflammation, fibrosis, angiogenesis, extracellular matrix (ECM) deposition, apoptosis and proliferation. PPARγ plays a key regulatory role in these biological processes. We further review strategies to modulate or target the PPARγ signalling pathway, highlight the related molecular mechanisms and recent clinical advances, and discuss potential possibilities for clinical translation and future perspectives.ConclusionsAlthough there is no direct evidence to support this, we found through a literature review that PPARγ may be involved in regulating various biological processes involved in the development of LFH. The PPARγ signalling pathway may be a potential therapeutic target for LFH, which provides new insights for future LFH research. Introduction Lower back pain, a long-standing health problem, not only causes disability but also contributes to the global burden of disease [1]. Lumbar spinal stenosis (LSS) is the main cause of lower back pain, and among the many factors leading to LSS, ligamentum flavum hypertrophy (LFH) plays a key role [2]. The healthy ligamentum flavum (LF) matrix consists of 30% parallel collagen fibres and 70% elastic fibres, which provide tissue support and maintain mechanical stability throughout the spine [3]. However, due to genetic, mechanical stress, degeneration, inflammation, and metabolic factors, a series of pathological changes and losses of biological function in the LF, including tissue structure destruction, elastic fracture and degradation, immune cell infiltration, fibre hypertrophy, scar formation, extracellular matrix (ECM) deposition and other problems, which may lead to LFH [4–6] (Fig. 1). When LFH occurs, it not only loses its inherent ability to protect the spinal cord and cauda equina and maintain the postural balance of the body but also may protrude into the spinal canal and press the dural sac, spinal cord, nerve root and cauda equina, becoming the main cause of LSS [2, 7, 8]. In recent years, LFH has been studied to some extent. Tissue fibrosis, as the main pathological process of LFH, has received increasing attention; however, the current treatment options are still limited [9]. Therefore, it is urgent to explore its potential mechanism and develop new therapeutic methods, which are conducive to the early recovery of patients. Risk factors for and pathological changes in ligamentum flavum hypertrophy (LFH). Various risk factors contribute to LFH, including advanced age, genetics, mechanical stress, intervertebral disc degeneration, and metabolic syndrome. These risk factors can lead to a series of pathological changes in the ligamentum flavum, such as inflammation, fibrosis, angiogenesis, cell senescence, immune cell infiltration, extracellular matrix (ECM) deposition and glucose/lipid disorder, resulting in LFH, which in turn leads to lumbar spinal stenosis Peroxisome proliferator activated receptors (PPARs) are a ligand-activated transcription factor nuclear receptor superfamily [10]. Three PPAR isotypes, α, δ, and γ, have been described, which have a combined role in controlling gene expression that plays a key role in lipid storage and mobilization, glucose metabolism, morphogenesis, and inflammatory responses [11]. Due to their universal expression, PPARs have positive effects on many conditions, including but not limited to diabetes, hypercholesterolemia, pulmonary arterial hypertension (PAH) [12], and anti-inflammatory and antineoplastic properties [13, 14]. Moreover, there is growing evidence that the PPAR signalling pathway is a suitable therapeutic target and a potential therapeutic target for several diseases [15]. A bioinformatics analysis revealed that the PPAR signalling pathway is significantly enriched in hypertrophic LF samples in the GSE113212 dataset, and analysis of the transcription factor–gene network revealed that PPARG plays important roles in LFH [16]. Our previous research also indicated that the PPAR signalling pathway is significantly downregulated during the development of LFH [5]. In addition, Cao et al. reported that acyl-CoA synthetase medium chain family member 5 (ACSM5) can inhibit the FABP4-mediated PPARγ signalling pathway, thereby suppressing lipid accumulation in LF cells and ultimately improving LFH [17]. Given these findings, in this review, for the first time, we investigate the potential therapeutic effect of PPARγ on LFH. Pathological processes of LFH Tissue fibrosis is a restorative process after tissue damage and is manifested mainly by the formation and deposition of excessive fibrous connective tissue and the replacement of original tissue by collagen-rich ECM [18, 19]. Many studies have shown that fibrosis is the main pathological mechanism of LFH [9, 20–23]. In healthy ECM, anabolic activity and catabolic activity are in balance [24], and the interaction between complex cytokines during fibrosis induces the synthesis of type I and III collagen in the ECM [18]. Disruption of the balance between tissue inhibitors of metalloproteinases (TIMPs) and matrix metalloproteinases (MMPs) leads to collagen accumulation and adverse matrix remodelling [25]. The observation of human samples by Okuda et al. revealed that in nonhypertrophic LF, the main component of the ECM was elastic fibres, the secondary component was collagen fibres, and the proportion of collagen fibres was significantly increased in hypertrophic LF [26, 27]. In addition, MMP-2 produced by fibroblasts, endothelial cells and other structural cells is related to fibrotic tissue remodelling and pathological collagen deposition [28, 29]. MMP-13 expression is increased in scar tissue fibrosis and plays a major role in fibrosis recovery [30, 31]. The interaction of MMPs and TIMPs can promote LF fibrosis through the degradation and remodelling of ECM components, which is an important molecular pathological mechanism of LFH [32–34] (Fig. 2). Schematic diagram of ECM components in normal LF (left) and hypertrophic LF (right). Compared with normal ECM, hypertrophic LF ECM is characterized by the degradation of elastic fibres, increased deposition of collagen fibres, the transformation of fibroblasts into myofibroblasts in increased numbers, the transformation of M2 macrophages into M1 macrophages, and increased fibronectin levels, inflammatory infiltration and angiogenesis Transforming growth factor β1 (TGF-β1) can regulate apoptosis, cell growth and cell differentiation; in addition, it is regarded as a key mediator of the process of fibre formation [35]. TGF-β1 not only increased the expression of type I, III, VI, VII, and X collagen; proteoglycans; and fibroconnexin but also decreased protease synthesis and inhibited matrix degradation, thereby enhancing ECM production [36]. Moreover, the enhanced expression of TGF-β1 in fibrotic tissues has been fully and favourably demonstrated [37]. Cao et al. applied exogenous TGF-β1 to treat cultured LF cells in vitro, and the results revealed that TGF-β1 could upregulate the expression of connective tissue growth factor (CTGF) in LF cells through the p38 mitogen-activated protein kinase (p38-MAPK) signalling pathway and cooperate with CTGF to stimulate the proliferation of LF cells and increase the expression of type I collagen and type III collagen in LF cells. This eventually leads to LFH [20]. In recent years, numerous studies have shown that inflammation is an important event in the process of fibrosis [38, 39]. Progressive LF fibrosis is driven by a persistent chronic inflammatory response [8, 40]. Inflammatory factors can induce LFH in a variety of ways. In addition to the nuclear factor-kappa B (NF-κB) signalling pathway, inflammatory factors also induce LFH through the p38-MAPK signalling pathway and Janus kinase/signal transducers and activators of transcription (JAK/STAT) signalling pathway [41–43]. In addition, some growth factors are involved in the occurrence of LF. Platelet-derived growth factor (PDGF) is related to tissue repair, scar formation, collagen deposition and various pathological processes of fibrosis [44]. PDGF-BB produced by fibroblasts and platelets plays important roles in wound healing and connective tissue formation [45, 46]. Excessive accumulation of PDGF-BB is related to pathological tissue fibrosis, including liver fibrosis [47], glomerular fibrosis [48], and LF fibrosis [44]. Due to the accumulation of mechanical stress during ageing and the accumulation of validated scar tissue, PDGF-BB is released from LF microdamage, which stimulates fibrosis in the early stage of LFH. Zhang et al. confirmed that the increased expression of PDGF-BB in LF is closely related to LFH in LSS [44]. CTGF can drive ECM production, angiogenesis, apoptosis and so forth. CTGF can promote the chemotaxis of fibroblasts [49] and can also increase the mRNA expression of type I collagen, integrin 5 and fibronectin in fibroblasts [50]. While CTGF is regulated by TGF-β1, TGF-β1 and CTGF have many common functions because CTGF is downstream of TGF-β1 [51]. Vascular endothelial growth factor (VEGF) induces the proliferation, migration and elongation of endothelial cells and plays important roles in angiogenesis and vascular permeability [52]. The VEGF/VEGFR signalling pathway plays important roles in vascular remodelling and angiogenesis, and VEGF overexpression can increase liver collagen deposition and accelerate fibrosis [53–55]. VEGF is involved in the fibrotic process of LFH by promoting the formation of new blood vessels [34]. PPARγ PPARγ is a ligand-activated transcription factor of a nuclear receptor superfamily that regulates target genes by forming a heterodimer with retinol-like X receptor (RXR) [56, 57]. These target genes are involved mainly in biological functions and pathways related to human metabolism, inflammation and immunity [58]. PPARγ is expressed in brown and white adipose tissue, the spleen and the large intestine, but it is expressed mainly in large amounts in adipose cells [59, 60]. The PPARγ gene includes a promoter and 50 exons that produce three mRNAs: PPARγ1, PPARγ2, and PPARγ3. These three different isotopes differ in ligand specificity, tissue distribution, and biological action. PPARγ1 and PPARγ3 mRNA are translated into the same protein, whereas PPARγ2 has one more NH2-terminal region, which is composed of 30 amino acids. Their expressions are also different. In contrast to the generality of PPARγ1 subtype expression in different cells, PPARγ2 expression is limited mainly to adipose tissue [61]. PPARγ1 is expressed at much lower levels in liver and muscle, although it is suggested that PPARγ1 expression in these tissues may be related to function [62]. The PPARγ2 subtype prevents lipotoxicity by enhancing the lipid buffering capacity of peripheral organs and promoting adipose tissue expansion and the proliferative response of beta cells to insulin resistance [63]. High concentrations of rosiglitazone inhibit the induction of lipopolysaccharide target genes in PPARγ-deficient macrophages, in part by activating PPARδ. These findings suggest that the activation and transinhibition functions of PPARδ and PPARγ in macrophages overlap [64]. There is already evidence that PPARγ ligands play an anti-inflammatory role in atherosclerotic [65] and inflammatory bowel disease models [66, 67], both natural and synthetic. It also affects the heart, kidneys, lungs, liver, skeletal muscle and adipose tissue and is associated mainly with metabolic abnormalities [68–70]. In conclusion, PPARγ has great therapeutic potential in many diseases, and its biological function needs to be further explored. Regulation of the PPARγ signalling pathway PPARγ is a type of NR regulated by synthetic ligands and endogenous cellular lipids that primarily regulate genetic programs affecting cell differentiation, metabolism, and insulin sensitization [71–73]. The nuclear receptor corepressor (NCoR) and the silencing mediator for retinoid and thyroid hormone receptors (SMRT) are cosuppressor proteins that comprise two interaction domains (IDs), named ID1 and ID2. The cosuppressor ID2 motif is closely correlated with the apo-PPARγ ligand-binding domain (LBD). The corepressor receptor interaction domain (RID) relies on the ID2 corepressor motif and is inhibited by the corepressor-selective inverse agonist T0070907 [74]. T0070907 not only inhibits full-length PPARγ transcription but also inhibits PPARγ target gene expression in 3T3-L1 preadipocytes [75]. In the TR-FRET biochemical peptide interaction experiment, T0070907 inhibited the binding of the cosuppressor ID2 peptide to the PPARγ LBD but decreased the binding of the coactivator peptide. However, the PPARγ agonist rosiglitazone increases the interaction of the TRAP220 coactivator ID2 motif peptide by increasing PPARγ transcription and decreasing the interaction of the corepressor ID2 peptide [74]. The conformation of transcriptionally active PPARγ bound to the coactivator peptide consists of three helix elements (helix 3, helix 4/5, and helix 12, a key regulatory element), which together form the interface of the coactivator peptide [71]. The coinhibitory peptide binds to the surface of activation function-2 by binding to helix 3 and helix 4/5, but unlike the active conformation, it does not contact helix 12 [76–78]. Activating the PPARγ signalling pathway helps LFH In recent years, an increasing number of studies have shown that the inhibition of activated PPARγ expression may be associated with the pathophysiological characteristics of LFH, including the inflammatory response, fibrosis, and collagen production [79] (Fig. 3). The potential mechanism and function of the PPARγ signalling pathway in LFH are discussed below. Role of activated PPARγ signalling in pathological progression. The activation of PPARγ signalling is associated with multiple biological processes, including the inhibition of inflammation, inhibition of fibrosis, inhibition of angiogenesis, inhibition of cell proliferation, inhibition of extracellular matrix (ECM) deposition, promotion of apoptosis, and regulation of glucose/lipid metabolism. These biological processes are involved in the development of LFH, which demonstrates the potential role of PPARγ in the treatment of LFH PPARγ inhibits the expression of inflammatory factors (Fig. 4) Molecular mechanisms of the anti-inflammatory effect of the PPARγ signalling pathway. Upon the activation of the PPARγ agonist, PPARγ inhibits the expression of inflammatory factors by inhibiting the AP-1, p38-MAPK, NF-κB and STAT signalling pathways, thereby suppressing the occurrence of LFH During the development of LFH, inflammatory cells aggregate and release a large number of inflammatory factors, and macrophage-derived TGF-β1 strongly induces extracellular collagen deposition, promoting the progression of LFH. Chen et al. reported that TGF-β1 promoted LF fibrosis by stimulating mesenchymal stem cells (MSCs) derived from LF, increasing the gene expression and protein levels of type I collagen, type III collagen and α-smooth actin (α-SMA) [80]. Park et al. applied different inflammatory factors to LF cells, and the results revealed that interleukin-1α (IL-1α), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), prostaglandin E2 (PGE2) and nitric oxide (NO) could significantly increase the mRNA expression of type I, V, and XI collagen and osteocalcin in LF cells [8]. Subsequently, Kang et al. cultured human LF cells with the superserum of degenerative herniated intervertebral disc tissue extract rich in inflammatory factors such as IL-1α, IL-6, TNF-α, PGE2 and NO; in LF cells, the expression of type III collagen, type XI collagen and osteocalcin significantly increased [81]. IL-1β and IL-6 can also induce LFH via the NF-κB signalling pathway, p38-MAPK signalling pathway, and JAK/STAT signalling pathway [41–43]. PPARγ regulates the expression of anti-inflammatory genes, including Arginase 1 and IL-10, and drives the development of macrophages towards the M2 phenotype and promotes the expression of M1 proinflammatory factors such as cyclooxygenase-2 (COX2), IL-6, TNF-α, NF-κB, and IL-1β [82]. Wang et al. reported that PPARγ is involved in macrophage differentiation to the M2 type [83]. PPARγ agonists significantly inhibited NF-κB, activator protein 1 (AP-1) and STAT signalling and downregulated the expression of macrophage inflammatory factors, including IL-1β, IL-6, TNF-α, inducible nitric oxide synthase (iNOS) and COX-2; this mechanism explains the antifibrotic effect of L-tetrahydropalmatine (L-THP) [84, 85]. PPARγ expression decreased the expression of COL-1, TGF-β1 and α-SMA in activated hepatic stellate cells‌[86]. In addition, Lu et al. reported that pirfenidone z, a PPARγ agonist, can directly downregulate the release of the inflammatory factors IL-6 and TNF-α in mice with pulmonary fibrosis[87]. In summary, inflammatory factors such as IL-6 and TNF-α promote collagen synthesis and thereby participate in the progression of LFH[8]. Moreover, due to its ability to inhibit the expression of these inflammatory factors, PPARγ can suppress collagen deposition and the occurrence of fibrosis, demonstrating its potential in the treatment of LFH and spinal canal stenosis [85–87]. PPARγ inhibits the TGF-β1/SMAD signalling pathway (Fig. 5) Molecular mechanisms of the antifibrotic effect of the PPARγ signalling pathway. Upon the activation of a PPARγ agonist, PPARγ inhibits tissue fibrosis by inhibiting TGF-β1/SMAD, CTGF and PDGF, thereby suppressing the development of ligamentum flavum hypertrophy TGF-β plays an important role in the pathogenesis of a range of diseases [88, 89]; the TGF-β1 subtype is associated mainly with tissue fibrosis [90, 91], and TGF-β1 is highly expressed in hypertrophic LF [5]. TGF-β1, in combination with its downstream pathway molecule Sma and the Mad-related protein‌ (SMAD) family, is involved in the regulation of many complex cellular physiological activities [5, 92]. Activation of SMAD3 or SMAD4 in the nucleus stimulates high expression of TGF-β1-targeting genes [93, 94]. Activation of the TGF-β1/SMAD pathway can inhibit TIMP-1 expression, promote MMP-2 expression and promote ECM deposition [95, 96]. Our previous study revealed that the TGF-β1/SMAD signalling pathway is an important regulatory mechanism leading to LFH [5]. Another study also confirmed that the activation of TGF-β/SMAD can lead to LFH, whereas miR-29b-3p can inhibit this pathway and thereby improve LFH [97]. PPARγ can exert antifibrotic effects by inhibiting TGF-β1. In the liver fibrosis model of Yu et al., PPARγ reduces the expression of TGF-β1 and phosphorylation of SMAD2/3 by inhibiting the NF-κB signalling pathway, thereby inhibiting the fibrosis promoted by the TGF-β1/SMAD pathway [98, 99]. Similarly, Chen et al. reported that crocin enhances the phosphorylation of PPARγ, inhibits the activity of the TGF-β1/SMAD pathway and reverses the occurrence of renal fibrosis [100]. Hata et al. suggested that PPARγ binds to SMAD3 and STAT3 in vascular smooth muscle cells, thereby inhibiting the downstream signalling of TGF-β1 and interfering with glucose metabolism and endothelial vascular cell proliferation [101]. PPARγ can prevent the stimulation of TGF-β1-induced fibronectin and collagen synthesis, and the elimination of SMAD-dependent collagen stimulation by PPARγ is achieved by targeting the p300 transcriptional coactivator [102–104]. Ghosh et al. studied the molecular mechanism underlying the elimination of the TGF-β1 signalling pathway by PPARγ in human fibroblasts and reported that PPARγ can block the SMAD-dependent transcriptional response. PPARγ not only prevented the interaction of activated SMAD2/3 with TGF-β1-induced transcriptional coactivators and the histone acetyltransferase p300 but also prevented the hyperacetylation of histone H4 at the COL1A2 site and the accumulation of p300 on the consistent SMAD binding DNA sequence. These results suggest that PPARγ can inhibit TGF-β1-induced collagen gene expression by blocking p300 recruitment and histone H4 hyperacetylation, thereby blocking the SMAD-mediated transcriptional response, which is an important mechanism underlying its anti-fibrosis effects [102]. PPARγ inhibits the NF-κB signalling pathway NF-κB is composed of many transcription factors and is involved in the regulation of various biological responses, such as proliferation, migration, inflammation, and apoptosis [105]. Nagai et al. reported that TNF-α and IL-1β can induce LFH by activating NF-κB signalling in LF cells [41]. Moreover, Saber et al. reported that the upregulation of PPARγ expression can inhibit the activation of the NF-κB signalling pathway, thereby reducing the expression of cytokines such as MMPs and ultimately attenuating the deposition of ECM. This study revealed that the activation of PPARγ can have antifibrotic effects through the NF-κB signalling pathway [106]. Another study also confirmed that PPARγ significantly negatively affects the transcriptional activity of the NF-κB signalling pathway and decreases the expression of IL-1β and TNF-α [107]. In addition, Yao et al. suggested that aspirin could inhibit MMP-2/9 through the PPARα/γ-NF-κB signalling pathway [108]. In addition, MMP-9 is involved in the activation of TGF-β1 and promotes the development of fibrosis [109, 110]. This evidence confirms that PPARγ can have an antifibrotic effect through the inhibition of the NF-κB signalling pathway. PPARγ blocks the p38-MAPK signalling pathway P38-MAPKs constitute an evolutionarily conserved class of MAPKs that regulate a variety of cellular processes through the transduction of extracellular signals [111, 112]. As an important member of the MAPK family, the p38-MAPK signalling pathway is involved in the development of cardiovascular diseases [113], neurodegenerative diseases [114], inflammation [115], intervertebral disc degeneration [24], cancer and other diseases [116]. Cheng et al. reported that the activation of p38-MAPK signalling can mediate ECM synthesis in intervertebral discs (IVDs) in diabetic rats. The data revealed that the expression of MMPs (MMP-3 and MMP-13) in the IVD tissues of diabetic rats increased after activation of the p38-MAPK signalling pathway, whereas the expression of TIMPs decreased [117]. Qi et al. reported that inhibition of the p38-MAPK signalling pathway can promote the expression of type II collagen and aggrecan [118]. This evidence indicates that if the activation of the p38-MAPK signalling pathway can be inhibited, ECM homeostasis can be restored, thus having important antifibrotic effects [24]. Moreover, the p38-MAPK signalling pathway is involved in the regulation of LFH, and TNF-α upregulates the expression of IL-6 in LF cells through the p38-MAPK signalling pathway, leading to LFH [42]. PPARγ may inhibit the p38-MAPK signalling pathway by blocking p38-MAPK phosphorylation, thereby reducing ECM deposition and thus inhibiting fibrotic processes [111, 112]. Ji et al. suggested that pioglitazone acts as a PPARγ agonist to control inflammation by intercepting the p38-MAPK signalling pathway and interferes with fibrosis [119]. This idea was also confirmed by Li et al., who reported that pioglitazone significantly reduced the expression of the p38-MAPK signalling pathway [120]. In addition, Han et al. reported that the expression of PPARγ in the PPARγ agonist group was greater than that in the p38 inhibition group and that the expression of p38-MAPK in the PPARγ agonist group was greater than that in the p38 inhibition group. These findings suggest that PPARγ may be downstream of p38-MAPK and that they are negatively regulated by each other [121]. As a result, the activation of PPARγ may block the expression of the p38-MAPK signalling pathway, to some extent preventing the development of fibrosis. PPARγ inhibits the Wnt/β-catenin signalling pathway (Fig. 6) Schematic diagram of the interaction between PPARγ and the Wnt/β-catenin signalling pathway. Upon the activation of the PPARγ agonist, PPARγ inhibits the activation of the Wnt signalling pathway, thereby reducing the expression of β-catenin, blocking fibroblast proliferation and differentiation, and promoting apoptosis The typical Wnt signalling pathway primarily controls cell proliferation, cell differentiation, apoptosis, and autophagy and plays important roles in the self-renewal of some tissues [122]. In the typical and highly conserved Wnt signalling pathway, extracellular Wnt ligands bind and activate membrane receptors via an autocrine/paracrine approach, which induces β-catenin stability and transfers it to the nucleus, where it is involved in the expression of genes that promote cell proliferation, survival, differentiation, and migration [123]. The typical Wnt signalling pathway can increase aerobic glycolysis and thus promote HSC activation, liver fibrosis and pulmonary fibrosis [124, 125]. Xu et al. reported that epithelial and mesenchymal cells activated by the TGFβ1-SMAD2/3 signalling pathway through Wnt/β-catenin contribute to lung fibrosis. Activation of the Wnt/β-catenin signalling pathway is required for the TGFβ1-SMAD2/3 signalling pathway during myofibroblast proliferation [126]. Some studies have shown that inhibition of transcription factor 7 (TCF7) downstream of the typical Wnt/β-catenin signalling pathway can promote LF apoptosis, ECM degradation, LF cell proliferation, and LF hypertrophy and fibrosis [127, 128]. PPARγ is clearly the opposite of the typical Wnt/β-catenin signalling pathway, where one is downregulated and the other is upregulated [129]. This characteristic is also reflected in fibrotic diseases [130, 131]. The Wnt signalling pathway plays an important role in the epigenetic inhibition of the HSC differentiation gene PPARγ [132]. Downregulation of the Wnt/β-catenin signalling pathway can induce PPARγ stimulation, and in many systems, PPARγ agonists can effectively reduce the expression of β-catenin [133, 134]. Dickkopf-1 (DKK1), a PPARγ agonist, inhibits Wnt signalling and blocks fibroblast differentiation [135]. In addition, Wnt/β-catenin signalling is activated during intestinal fibrosis, whereas the Wnt/β-catenin pathway is inhibited by PPARγ agonists [136]. The Wnt/β-catenin signalling pathway and TGF-β1 promote radiation-induced fibrosis, which is inhibited by PPARγ [137]. In addition, during the pathological process of LFH, apoptosis is significantly inhibited [138]. PPARγ also plays an important role in the apoptosis of synovial fibroblasts. Three PPARγ agonists, thiazolidinedione, 15d-PGJ2 and troglitazone, can induce the apoptosis of synovial fibroblasts in vitro [139, 140]. This evidence suggests that PPARγ may regulate the development of LFH through the Wnt signalling pathway. However, given the limited research on LFH, these hypotheses need to be further confirmed through corresponding studies in the future. PPARγ inhibits NFAT A significant increase in nuclear factor of activated T-cell 2 (NFAT2) expression was detected in patients with renal fibrosis, and the use of the NFAT2 inhibitor 11R-VIVIT alleviated renal tubulointerstitial fibrosis [141]. NFAT family members were originally thought to be transcription factors expressed in many immune cells and involved in the transcription of immune response-related genes and cytokine genes [141]. Activation of NFAT not only promotes the transcription of hypertrophic genes but also promotes the activation of fibroblasts [142]. The expression and secretion of Angptl2 in LF is upregulated by mechanical tensile stress via the calcineurin/NFAT signalling pathway [143]. However, Angptl2 can also partially mediate the expression of TGF-β1 induced by mechanical tensile stress [143]. NFAT is a key factor that induces pathological cardiomyocyte hypertrophy. NFAT activity increases during myocardial fibrosis. PPARγ can block NFAT DNA transcription and binding activity through the NFAT signalling pathway and inhibit cardiomyocyte hypertrophy [144]. Du et al. reported that ox-LDL activates NFAT in the cytoplasm of macrophages to transfer it to the nucleus, after which NFAT binds directly to PPARγ in the nucleus, which downregulates the transcriptional activity of NFAT [145]. Abubakr Chaudhry’s study further confirmed that pioglitazone can reduce the increase in NFAT activity caused by hypoxia, thereby inhibiting cardiac hypertrophy [146]. In addition, Yao et al. reported that n-3 PUFAs, as anti-inflammatory fatty acids, inhibit fibrosis and protect against CD (Crohn’s disease) via the PPARγ/NFAT signalling pathway [147]. These studies suggest that PPARγ can participate in LFH through the inhibition of NFAT activity. PPARγ and PDGF PDGF is one of four isomers of PDGF, namely, A, B, C and D, which are important mitogens of mesenchymal cells and can stimulate the full contraction of collagen gel [148], stimulate the expression of HSCs, regulate the migration of HSCs, and promote vascular remodelling [149]. On the one hand, PDGF penetrates fibrosis through chemical inducers and mitotic thrusting [150]; on the other hand, it enhances fibrosis through synergistic action with TGF-β1 [151]. The PDGF signalling pathway is associated with and even appears to carry a core function in the development of fibrotic disease, which involves loss of tissue function and progressive scarring due to mesenchymal cell proliferation and ECM deposition. Compared with that in normal liver tissue, the expression of PDGFRb and PDGF-B in cirrhotic liver tissue is increased [152, 153]. Macrophages produce chemokines, including PDGF, fibroblast growth factor (FGF), and VEGF [154, 155], which help attract other cells within the ECM to form granulation tissue while promoting fibroblasts to replace the temporary ECM with higher-intensity ECM [156]. Nilotinib is considered a PDGFR inhibitor and has been shown to inhibit PDGF-stimulated fibrosis [157]. In addition, imatinib mesylate has an inhibitory effect on PDGF, alleviates radiation-induced fibrosis and prevents fibrosis induced by bleomycin in mice. The inhibition of PDGF is one of the mechanisms underlying the anti-fibrosis effect of imatinib, which also suggests that the use of PDGF inhibitors may be a potential anti-fibrosis mechanism [157–159]. Glabridin can upregulate the expression of PPARγ and can be regarded as a PPARγ agonist. Zhang et al. reported that glabridin upregulated the expression of PPARγ and inhibited the stimulation of mouse hepatic stellate cells by PDGF-BB, thereby protecting against liver fibrosis [160]. The identification of curcumin as a PPARγ agonist has long been reported, and Zhang et al. confirmed that PPARγ disrupts the PDGF-bR/ERK cascade and inhibits downstream angiogenesis in response to curcumin [161]. Therefore, the inhibition of PDGF, one of the many mechanisms underlying the anti-fibrosis effects of PPARγ, is promising as a potential therapeutic target. PPARγ and CTGF CTGF is a pro-fibrotic growth factor involved in fibroblast proliferation, angiogenesis, cell adhesion, and ECM synthesis [135]. TGF-β1 plays a key role in vascular fibrosis by promoting the production of CTGF [25]. Zhong et al. reported a significant increase in CTGF expression in hypertrophic LF tissues, which was positively correlated with the thickness of the LF [10]. CTGF can promote the synthesis of type III collagen and type I collagen in LF cells. PPARγ blocks the secretion of CTGF, and the expression levels of these genes are negatively correlated with fibrosis [25]. Leask et al. also reported that PPARγ can reduce CTGF expression [162]. In addition, PPARγ can antagonize cytokines related to fibrosis, such as TGF-β1 and CTGF [102–104]. PPARγ was able to inhibit the stimulatory effect of TGF-β1 on CTGF, revealing its antifibrotic effect [103]. The findings of Han et al. suggest that PPARγ and p38-MAPK may coregulate CTGF [121]. PPARγ inhibits VEGF Angiogenesis is a complex process that depends on the interaction of vascular endothelial cells, macrophages, fibroblasts, and the ECM to form new capillaries in the microvascular bed. This process depends on the coordination of proantiangiogenic factors [163, 164]. Some researchers have reported that the level of VEGF is significantly increased in the hypertrophic LF and that the blood vessel density in the hypertrophic LF is also increased [34, 165–167]. Many studies have confirmed that VEGF-mediated angiogenesis may be a key mechanism of LFH [166, 168]. The mechanism through which PPARγ inhibits angiogenesis may be related to the following five aspects: (1) targeting protein kinase B (PKB/Akt); (2) simultaneously upregulating platelet reactivity protein receptor CD36 and the angiogenesis inhibitor maspin; (3) inhibiting the activation of MAPK; (4) increasing the expression of MMP inhibitors and plasminogen activator inhibitor-1 (PAI-1); and (5) inhibiting the expression of VEGF and its receptor [169–172]. Park et al. reported that PPARγ inhibits renal fibrosis by inhibiting the VEGF signalling pathway, which has therapeutic potential for improving renal function [173]. Aljada et al. also reported that both rosiglitazone and pioglitazone inhibited VEGF-stimulated angiogenesis, in addition to inhibiting endothelial cell migration [174]. As a result, PPARγ agonists can participate in the process of inhibiting LFH by inhibiting VEGF. Regulation of metabolic syndrome by PPARγ Metabolic syndrome is a group of metabolic disorders characterized by obesity, dyslipidaemia, hyperglycaemia and hypertension and is closely related to the occurrence of many diseases [175]. Diabetes, as the most common metabolic syndrome, is among the important risk factors for LFH [176–178]. The PPARγ signalling pathway has been used in the clinical treatment of type 2 diabetes, and its effective regulation of glucose metabolism may be beneficial against fibrosis [176–178]. In addition to affecting glucose metabolism, lipid metabolism also has different effects on the process of fibrosis [179]. Disruption of lipid metabolism can promote the transformation of fibroblasts into myofibroblasts, which leads to pulmonary fibrosis [180]. Similarly, in liver fibrosis, Feng et al. reported that the initial stage of HSC activation is the transdifferentiation of stationary HSCs into myofibroblast-like cells (MFB), during which the loss of lipid droplets is observed [181, 182]. Lipid loss and STAT3-mediated metabolic reprogramming are essential for the initiation phase of HSC activation, which is caused by DNA 5mC hypermethylation on the promoter of the SOCS3 and PPARγ genes [183]. 5-Aza-2’-deoxycytidine (5-aza), a DNA methyltransferase inhibitor, can effectively reverse epigenetic inhibition of the PPARγ gene to prevent lipid loss, thereby preventing HSC-MFB transdifferentiation [184]. Wei et al. reported that lipid drop loss can be regarded as an important sign of HSC-MFB transdifferentiation in the initial phase of HSC activation. This can be attributed to 5mC methylation in the PPARγ promoter region of the lipogenic gene, which reduced PPARγ expression and impaired lipogenesis. In addition, this regulation of epigenetic inheritance by 5mC methylation of PPARγ was also observed in mouse pulmonary fibrosis [185]. PPARγ may become a new antifibrotic therapeutic target and provide a new direction for the treatment of LFH. Targeted regulation of the PPARγ signalling pathway to treat LFH In recent years, the development of PPARγ agonists has emerged as a potential strategy to treat a variety of diseases, such as pulmonary fibrosis, renal fibrosis, nonalcoholic fatty liver disease, pathological cardiac fibrosis and ovarian fibrosis. PPARγ activators exhibit significant antifibrotic effects in various diseases (Table 1). Table 1Potential application of PPARγ activator in antifibrotic treatmentReferencesSpeciesTarget organs/cellsSignaling pathwaysActivatorsEffectsLv et al. [88]MiceLung/fetal lung fibroblastsWnt/GSK−3β/β-cateninTGF-β1/SMAD2/3PirfenidoneInhibiting inflammatory response and ECM deposition.Chen et al. [100]MiceKidneyTGF-β1/SMAD 2/3CYP4A11/PPARγNF-κBCrocinAnti-inflammatory and anti-oxidative effects.Ghosh et al. [102]HumanSkin/fibroblastsTGF-β1/SMAD2/3TroglitazoneInhibit collagen synthesis and control TGF-β1-dependent fibrotic processes.Ghosh et al. [103]HumanSkin/fibroblastsTGF-β1/SMADGW9662Abrogating of TGF-induced stimulation of collagen gene expression, myofibroblast transdifferentiation, and SMAD-dependent promoter activity.Saber et al. [106]RatKneeNF-κBCurcuminInhibiting inflammatory response and ECM deposition.Yao et al. [108]MiceCeliac acrophagesPPARα/γ-NF-κBAspirinAnti-inflammatory and decreases ECM degradation by inhibits MMPs expression and promotes TIMPs expression.Bao et al. [145]RatCardiac myocytescalcineurin/NFATRosiglitazoneInhibiting the ET−1-induced increase in protein synthesis, surface area, calcineurin enzymatic activity, and protein expression.Zhang et al. [161]MiceLiver/hepatic stellate cellsPDGF-BB/TGF-β1GlabridinSuppressing the liver fibrosis, decreased collagen deposition, anti-inflammatory and anti-oxidative stress effects, suppressing inflammation and oxidative stress. Potential application of PPARγ activator in antifibrotic treatment Wnt/GSK−3β/β-catenin TGF-β1/SMAD2/3 TGF-β1/SMAD 2/3 CYP4A11/PPARγ NF-κB Currently, known PPARγ agonists include natural ligands as well as synthetic ligands. Most of the compounds identified are selective PPARγ modulators (SPPARMs) that act as partial agonists to activate PPARγ gene expression. Unlike synthetic PPARγ agonists such as pioglitazone, natural ligands such as biotin A, genistein, sargasquinic acid, resveratrol, sargasquinic acid, and saponin alcohol can also activate PPARα in some cases. However, natural ligands such as neophenol, santalol, and santalol can activate the PPARγ-dimer chaperone RXR with fewer side effects [186]. Targeting PPARγ regulation Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), key components of ω-3PUFA in fish oil, can activate PPARγ and significantly increase PPARγ mRNA transcription [187]. Han et al. reported that Shentong Zhuyu Decoction promoted PPARγ expression by decreasing CTGF levels and p38-MAPK activity [121]. Curcumin upregulated PPARγ expression and reversed the increase in the expression of MMP-1 and MMP-13 [188]. Sesame oil reduces collagen deposition and fibrosis by increasing the expression of PPARγ and TIMP-1, reducing the expression of α-SMA and inhibiting the expression of MMP-2 and MMP-9 [189]. Aspirin can inhibit the release and expression of MMP-2/9 by upregulating PPARα/γ gene expression [108]. Current research on PPARγ PPARγ agonists are mainly used to treat type 2 diabetes, but their use is limited due to severe side effects [186]. In addition to improving diabetes, PPARγ appears to have other therapeutic potential. Legchenko et al. reported that pioglitazone, a PPARγ agonist, can regulate the transcription, epigenetic inheritance and metabolism of pathological processes such as myocardial hypertrophia, myocardial contraction, fibrosis and fatty acid transport/oxidation through the miRNA/mRNA network to normalize them and treat cardiovascular and pulmonary diseases [190]. This view is supported by the findings of Anirban Banik et al., who reported that deoxyimaging peptide (DEP), a novel PPARγ agonist, downregulates STAT-3-mediated collagen gene expression in a PPARγ-dependent manner, demonstrating its antifibrotic potential in cardiac hypertrophy [191]. In a study by Chen et al., rosiglitazone, a PPARγ agonist that inhibits fibrosis, alleviated secondary lymphedema and fibrosis after posterior lymph node dissection [192]. Yang et al. studied the effects of pioglitazone on the kidney and reported that pioglitazone has beneficial effects on tubulointerstitial fibrosis, which is related to an increase in PPARγ expression [193]. Dong et al. demonstrated that the PPARγ agonist rosiglitazone inhibits endothelium-to-mesenchymal transformation (EndoMT) and alleviates hepatic fibrosis [194]. Of course, PPARγ not only has benefits but also has risks and harms. Wan et al. reported that the activation of PPARγ inhibits the formation of osteoblasts and activates the formation of osteoclasts, thereby reducing bone formation while maintaining or increasing bone resorption, and diabetic patients who take rosiglitazone for a long time are more likely to suffer fractures [195]. Although studies have shown that PPARγ agonists can be used to treat fibrosis, clinical studies on the development of LFH are lacking. Experimental support is lacking, and the efficacy, dosage, and side effects of these drugs are poorly understood. This provides a direction for subsequent research. Conclusion and future perspectives LFH is a complex pathological process mediated by many factors, including heredity, mechanical stress, degeneration, inflammation, and metabolism. Therefore, it is necessary to explore new mechanisms and develop potential therapeutic targets for LFH. As previously mentioned, activation of the PPARγ signalling pathway may contribute to the remission of LFH, including inhibition of the inflammatory response, inhibition of collagen synthesis, promotion of apoptosis, and inhibition of proliferation. Therefore, future studies should focus on solving the following problems: First, on the basis of the currently accessible LFH literature, direct evidence that PPARγ regulates the development of LFH is limited, and in many contexts, it is urgent to investigate whether PPARγ can delay or inhibit the occurrence of LFH through in vitro and in vivo research (Fig. 7). In addition, the triggering factors of PPARγ signalling pathway dysregulation and the mechanism underlying the recovery of PPARγ signalling pathway dysregulation during LFH are still unclear. Studies on the targeted regulation of fibrosis by PPARγ to inhibit LFH may provide new insights for the treatment of LSS in the future. Illustration of putative future prospects of therapeutic targets linking PPARγ with LFH, including the TGF-β1/SMAD signalling pathway, NF-κB signalling pathway, p38-MAPK signalling pathway, JAK/STAT signalling, and Wnt/β-catenin signalling pathway Acknowledgements The figures were created by Bioender (https://app.biorender.com/). Abbreviations Ligamentum flavum hypertrophy Peroxisome proliferator activated receptors γ Lumbar spinal stenosis Ligamentum flavum Extracellular matrix Pulmonary arterial hypertension Acyl-CoA synthetase medium chain family member 5 Retinol-like X receptor Nuclear receptor corepressor Silencing mediator for retinoid and thyroid hormone receptor Interaction domains Ligand-binding domain Receptor interaction domain Metalloproteinases Matrix metalloproteinases Transforming growth factor β1 Connective tissue growth factor ‌p38 mitogen-activated protein kinase Nuclear factor-kappa B Janus kinase/Signal transducers and activators of transcription Platelet-derived growth factors Vascular endothelial growth factor Mesenchymal stem cells α-smooth actin Interleukin Tumor Necrosis Factor-α Prostaglandin E2 Nitric oxide Cyclooxygenase−2 Activator Protein 1 Tetrahydropalmatine Collagen Sma and Mad-related protein Intervertebral disc Transcription factor 7 Dickkopf−1 Nuclear factor of the activated T cell 2 Fibroblast growth factor Extracellular regulated protein kinases Protein kinase B Plasminogen Activator Inhibitor−1 Myofibroblast-like cells Aza−2 ‘deoxycytidine Eicosapentaenoic acid Docosahexaenoic acid Deoxyimaging peptide Endothelium-to-mesenchymal transformation Author contributions Xue Chen drafted the original manuscript. Shanxi Wang was responsible for the conception, design and final approval. Chen Zhu, Ye Tian and Tuanjiang Liu took part in revising the grammar. Shuhan Yang and Yuan Zeng participated in the production of figures and tables. Chen Liang and Bo Zhang took part in literature search. All the authors read and approved the final manuscript. Funding This work was supported by the NSFC Seed Funding Project of Xi’an Honghui Hospital (Grant No. 2025zz-qn07), Research Project of Xi’an Municipal Health Commission (Grant No. 2026qn08), and Faculty Independent Exploration and Innovation Project, Xi’an Jiaotong University (Grant No. xzy012026154). Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no conflict of interest. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.